

**Notice Regarding Limited Distribution Plan for AYVAKIT™ (avapritinib) and GAVRETO™ (pralsetinib)
– September 8, 2020 –**

This notice provides information for 340B covered entities about how to acquire AYVAKIT and GAVRETO at the 340B ceiling price. Blueprint Medicines manufactures the following packaging configurations:

PRODUCT NAME	NDC	STRENGTH	PACKAGE SIZE
AYVAKIT	72064-130-30	300 mg	30 tablets
AYVAKIT	72064-120-30	200 mg	30 tablets
AYVAKIT	72064-110-30	100 mg	30 tablets
GAVRETO	72064-210-90	100 mg	90 capsules
GAVRETO	72064-210-60	100 mg	60 capsules

To ensure that patients being treated with AYVAKIT and GAVRETO receive high quality supportive care and experience optimal therapeutic adherence, Blueprint Medicines has developed a limited distribution plan designed to achieve these goals. All pharmacies – 340B and otherwise – are subject to this plan.

If your pharmacy (a) holds a specialty pharmacy accreditation from URAC or ACHC or is a National Cancer Institute designated cancer center, and (b) operates a medically integrated pharmacy that only dispenses to patients of record at your facility, we invite you to join our network of pharmacies served by our specialty distribution partners: ASD Healthcare, Cardinal Specialty, McKesson Plasma & Biologics, McKesson Specialty Health, and Oncology Supply. To apply, please call 1-888-258-7768, Monday-Friday, 8 AM-8 PM Eastern Time.

If your pharmacy does not qualify for inclusion in our network, or if you choose not to apply to join our network, you can still access AYVAKIT and GAVRETO through one of our specialty pharmacies that specialize in oncology and rare diseases: Biologics and PANTHERx Rare Pharmacy. Provided you have a 340B contract pharmacy relationship with one of these specialty pharmacies, product will be shipped directly to the pharmacy, which will dispense the product to the patient. The covered entity's contract pharmacy relationship will be verified using the OPA database.

Blueprint Medicines offers the 340B ceiling price to all covered entities who meet the requirements described above, except those that are ineligible for 340B pricing for drugs, like AYVAKIT and GAVRETO, that are designated by FDA for an orphan use.¹

Blueprint Medicines takes its participation under the 340B program seriously and makes every effort to ensure that our products are available to all 340B covered entities in a manner that is no more restrictive than for its non-340B customers. If you have any questions about this plan, or any difficulty obtaining AYVAKIT or GAVRETO, please contact Blueprint Medicines directly at 1-888-258-7768.

¹ These covered entities are free-standing cancer hospitals, critical access hospital, rural referral centers, and sole community hospitals. See 42 U.S.C. § 256b(e).